Revista Urología Colombiana / Colombian Urology Journal, Table of Contents

CC BY-NC-ND 4.0 · Revista Urología Colombiana / Colombian Urology Journal 2018; 27(01): 048-054
DOI: 10.1055/s-0038-1637015

Original Article | Artículo Original

Sociedad Colombiana de Urología. Publicado por Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

Prevalencia de Eventos Cardiocerebrovasculares en Pacientes con Cáncer de Próstata en Manejo con Bloqueo Androgénico con Análogo de GNRH

Prevalence of Cardiovascular Events in Patients with Prostate Cancer that Require Androgen Deprivation Therapy with Gonadotroping Hormone-Releasing Hormone Agonists

José Luis Poveda

¹Departamento de Urología, Hospital Central de la Policía y Hospital Militar Central, Bogotá, Colombia

,

Cesar González

¹Departamento de Urología, Hospital Central de la Policía y Hospital Militar Central, Bogotá, Colombia

,

William Quiroga

¹Departamento de Urología, Hospital Central de la Policía y Hospital Militar Central, Bogotá, Colombia

,

Margarita Zapata

¹Departamento de Urología, Hospital Central de la Policía y Hospital Militar Central, Bogotá, Colombia

,

Sebastián Baena

¹Departamento de Urología, Hospital Central de la Policía y Hospital Militar Central, Bogotá, Colombia

› Author Affiliations

Resumen

Objetivo Determinar la prevalencia de eventos cardiocerebrovasculares en pacientes con cáncer de próstata que son manejados con bloqueo hormonal, con análogo de la GNRH.

Materiales y Métodos Se realizó un estudio de corte transversal, en pacientes con cáncer de próstata que fueron manejados con bloqueo hormonal con análogo de la GNRH, con un mínimo de seguimiento de 2 años, entre los años 2004 y 2014. Paciente con eventos que acaecieron en el primer año de observación, fueron excluidos. Se evaluaron las comorbilidades de los pacientes y se clasificaron en diferentes grupos de riesgo, según el índice de comorbilidades ACE27. Se determinó la prevalencia de eventos cardiovasculares definidos como un episodio de infarto agudo de miocardio, de angina y de eventos cerebrovasculares durante la observación. Se comparó la prevalencia de acuerdo al subgrupo de riesgo ACE27.

Resultados Se incluyeron 281 pacientes. La comorbilidad más común fue la hipertensión arterial con un 45% y por último la diabetes mellitus con un 17%. La prevalencia de eventos cardiovasculares y cerebrovasculares en la población general fue del 7,5% para cada evento. Se clasificaron los pacientes según el índice de comorbilidades ACE-27 tendiendo el 39% de los pacientes un índice de comorbilidad bajo y el 7% alto. La prevalencia de eventos cardiocerebrovasculares varía desde el 5% en bajo riesgo, hasta el 25% en grupo de alto riesgo.

Conclusiones La prevalencia de eventos cardiocerebrovasculares fue del 7,5% en la población de estudio. En el grupo de alto riesgo ACE27 con el uso de análogo de GNRH, se determinó una mayor prevalencia de eventos cardiocerebrovasculares.

Abstract

Objective To determine the prevalence of cardiovascular events in patients with prostate cancer who were being managed androgen deprivation therapy with gonadotroping hormone-releasing hormone (GHRH) agonists.

Materials and Methods A cross-sectional analysis was done in patients with prostate cancer that were treated with androgen deprivation therapy with GHRH agonists, between 2004 and 2014. Follow-up of 2 years was required. Patients who developed cerebrovascular and cardiovascular events within the first year of treatment were excluded. Comorbidities were evaluated and classified in groups of risk, according to the adult comorbidity evaluation index (ACE27). General prevalence of cardiovascular events was established. Prevalence between comorbidity risk groups were quantified and compared.

Results 281 patients were included. Among all comorbidities arterial hypertension was the most frequent (45%) and the less frequent was diabetes mellitus (17%). The prevalence of cardiovascular and cerebrovascular events in general population was 7.5%. Patients were classified according to the ACE27 index score resulting in 39% of patients having mild comorbidity score and 7% as severe comorbidity. Between patients classified as having mild comorbidity, prevalence of 5% was found and 25% of prevalence in the severe comorbidity group.

Conclusion The prevalence of cardiovascular events was 7.5% in the studied population. In the severe risk group, according to the ACE 27 index, the prevalence of cardiovascular events increases till 25%.

Palabras Clave

Palabras Clave

cáncer de próstata - prevalencia - análogos GNRH - eventos cardiocerebrovasculares - ACE27 - estudio descriptivo

Keywords

Keywords

prostate cáncer - prevalence - luteinizing hormone-releasing hormone (LHRH) agonists - ACE27 - descriptive study

Bibliografía
1 O'Farrell S, Sandström K, Garmo H. , et al. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy. BJU Int 2016; 118 (03) 391-398
2 Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24 (27) 4448-4456
3 D'Amico AV, Denham JW, Crook J. , et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25 (17) 2420-2425
4 Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. ; Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110 (07) 1493-1500
5 Uttley L, Whyte S, Gomersall T. , et al. Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics 2017; 35 (07) 717-726
6 Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009; 302 (08) 866-873
7 Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3 (11) e442
8 Alan J. . Wein M, PhD (Hon), FACS, Louis R. Kavoussi, MD, MBA, Alan W. Partin, MD, PhD and Craig A. Peters, MD. Campbell-Walsh Urology, 11th Edition. 11 th ed. Elsevier, editor: Elsevier ed; 2016. 4168 p.
9 Siegel RL, Fedewa SA, Miller KD. , et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin 2015; 65 (06) 457-480
10 Gandaglia G, Sun M, Popa I. , et al. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study. BJU Int 2014; 114 (6b): E82-E89
11 Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 2014; 65 (03) 565-573
12 Nguyen PL, Alibhai SM, Basaria S. , et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67 (05) 825-836
13 Carneiro A, Sasse AD, Wagner AA. , et al. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol 2015; 33 (09) 1281-1289
14 Sciarra A, Fasulo A, Ciardi A. , et al. A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine (Baltimore) 2016; 95 (27) e3845
15 Abizanda Soler P, Paterna Mellinas G, Martínez Sánchez E, López Jiménez E. Evaluación de la comorbilidad en la población anciana: utilidad y validez de los instrumentos de medida. Rev Esp Geriatr Gerontol 2010; 45 (04) 219-228
16 Gandaglia G, Sun M, Popa I. Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy; a population based study. Clinical genitourinary cancer: Elsevier Inc; 2015: 123-130
17 D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299 (03) 289-295